725686-47-5

Basic information

• Product Name: 3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine
• Synonyms: 3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine;5-tert-butyl-2-(3-methoxyphenyl)pyrazol-3-amine;5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-ylamine
• CAS NO: 725686-47-5
• Molecular Formula: C₁₄H₁₉N₃O
• Molecular Weight: 245.32016
• Mol File: 725686-47-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine(725686-47-5)
• EPA Substance Registry System: 3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine(725686-47-5)

Safety Data

• Hazardous Substances Data: 725686-47-5(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry Research:
3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine is used as a research compound for exploring its potential pharmacological properties and applications in the treatment of various diseases and disorders. Its unique structure and functional groups make it a promising candidate for drug discovery and development.
Used in Chemical Synthesis:
3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine is used as a chemical building block for the synthesis of other organic compounds. Its versatile structure and functional groups allow for the creation of new compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.
Used in Drug Discovery:
3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine is used as a lead compound in drug discovery efforts. Its potential pharmacological properties and unique structure make it a valuable starting point for the development of new therapeutic agents.
Used in Pharmaceutical Industry:
3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine is used as a key intermediate in the synthesis of pharmaceutical compounds. Its presence in the molecular structure can contribute to the desired biological activity and therapeutic effects of the final drug product.
Used in Materials Science:
3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine is used as a component in the development of new materials with specific properties. Its unique structure and functional groups can be utilized to create materials with improved performance characteristics, such as enhanced stability, reactivity, or selectivity.
Used in Agrochemical Industry:
3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine is used as a starting material for the synthesis of agrochemicals, such as pesticides and herbicides. Its potential biological activity and unique structure make it a valuable resource for the development of new and effective agrochemical products.

Upstream product

• 59997-51-2 trimethylacetylacetonitrile 
• 536-90-3 m-Anisidine 

Downstream Products

• 725686-48-6 1-[3-tert-butyl-1-(3-methoxyphenyl)-1H-pyrazol-5-yl]-3-(naphthalen-1-yl)urea 
• 1443252-53-6 5-tert-butyl-2-[3-(2-morpholin-4-ylethoxy)phenyl]-2H-pyrazol-3-ylamine 
• 1443251-70-4 1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-isopropyl[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]urea 
• 869663-62-7 3-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)phenol 
• 946050-88-0 5-tert-butyl-2-[3-(2-dimethylaminoethoxy)phenyl]-2H-pyrazol-3-ylamine 
• 1443252-63-8 N-(3-tert-butyl-1-{3-[2-(dimethylamino)ethoxy]phenyl}-1H-pyrazol-5-yl)carbamic acid 2,2,2-trichloroethyl ester 
• 945995-64-2 4-nitrophenyl [3-tert-butyl-1-(3-methoxyphenyl)-1H-pyrazol-5-yl]carbamate 

Relevant articles and documents

KINASE INHIBITORS

Disclosed are compounds having [1,2,4]triazolo[4,3-a]pyridine groups and pharmaceutically acceptable salts thereof. The compounds are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT

Disclosed are compounds having [1,2,4]triazolo[4,3-a] pyridine groups and pharmaceutically acceptable salts thereof. The compounds are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Anti-inflammatory medicaments

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.

MODULATION OF PROTEIN FUNCTIONALITIES

New methods for the rational identification of molecules capable of interacting with specific naturally occurring proteins are provided, in order to yield new pharmacologically important compounds and treatment modalities. Broadly, the method comprises the steps of identifying a switch control ligand forming a part of a particular protein of interest, and also identifying a complemental switch control pocket forming a part of the protein and which interacts with said switch control ligand. The ligand interacts in vivo with the pocket to regulate the conformation and biological activity of the protein such that the protein assumes a first conformation and a first biological activity upon the ligand-pocket interaction, and assumes a second, different conformation and biological activity in the absence of the ligand-pocket interaction. Next, respective samples of said protein in the first and second conformations are provided, and these are screened against one or more candidate molecules by contacting the molecules and the samples. Thereupon, small molecules which bind with the protein at the region of the pocket may be identified. Novel protein-modulator adducts and methods of altering protein activity are also provided.

Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors

A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

Anti-inflammatory medicaments

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.